A pathology report is only as reliable as the specimen behind it. Before a slide ever reaches a microscope, tissue has already passed through collection, labeling, transport, and fixation, each step capable of introducing variability that no downstream analysis can reverse. This stretch of the workflow, the pre-analytical phase pathology depends on, receives far less standardization and technology investment than the stages that follow it. Labs can digitize and automate everything after the slide is made, while the phase that determines what data exists in the first place stays largely manual and undocumented.
Diagnostic Accuracy Cannot Exceed Specimen Quality
Diagnostic interpretation is bounded by the specimen’s physical condition at the moment it reaches the pathologist. Once a specimen undergoes gross dissection and sectioning, that anatomic alteration is irreversible, so orientation errors, delayed fixation, or fragmentation introduced earlier cannot be corrected at the microscope.
A pathologist can only interpret the specimen in front of them; when that specimen carries incomplete or degraded data, no amount of skill or downstream technology can supply what was never captured. Margin integrity, tumor dimension, and lymph node yield are established during specimen acquisition and early handling, not during interpretation, which means errors introduced at the bench surface later as diagnostic uncertainty, regardless of how the case is analyzed afterward. Quality investment concentrated entirely on whole slide imaging and AI-assisted grading cannot recover data lost before the specimen became a slide. This is why catching pre-analytical errors upstream matters more than refining what happens after them: treating the pre-analytical phase as a preliminary formality has left it under-resourced relative to its actual impact on diagnostic accuracy.
The Hidden Rate of Pre-Analytical Error
Pre-analytical error has historically been difficult to quantify because most institutions rely on passive reporting, meaning errors surface only when someone formally documents them. A 2026 systematic review and meta-analysis in BMJ Open Quality, drawing on nearly 2.8 million surgical pathology cases, found a pooled pre-analytic error prevalence of 16.71 per 1,000 cases.[1]
The more consequential finding is the gap behind that number: reported surgical pathology errors averaged just 4.94 per 1,000 cases across the same literature, while actively identified laboratory errors, found through direct observation and audit rather than voluntary reporting, reached 40.17 per 1,000. The researchers described this as a substantial discrepancy indicating that documented error rates understate the true burden of technical errors in specimen handling. Active detection consistently surfaces more problems than routine reporting does, which means labs relying on incident logs alone are working from an incomplete picture of their own pre-analytical performance.
How Errors at the Bench Translate to Lost Diagnostic Data
The consequences of pre-analytical error are not abstract. Specific handling failures convert directly into diagnostic data that cannot be recovered later, regardless of how sophisticated the downstream analysis is.
- Fixation Timing And Tissue Integrity
Delayed fixation allows autolysis to begin, the self-digestion of tissue that degrades cellular detail, breaks down enzymes, and increases eosinophilia before the specimen ever reaches formalin in adequate volume. Inadequate fixative volume compounds the problem: standard guidance calls for a fixative-to-tissue ratio of 15 to 20 to 1, and specimens fixed below that threshold risk incomplete preservation and physical distortion that later staining and imaging cannot correct. Once autolytic change has occurred, no amount of downstream processing restores the original cellular architecture.
- Handling Failures That Never Make the Report
Some of the most consequential handling errors are also the most subtle. For instance, tissue collected in an suboptimal fixative may arrive at the lab less suitable for specialized diagnostic testing, while delicate specimens placed inadvertently without proper orientation can complicate downstream sectioning. Extending the same standardized, meticulous care to specimen handling as healthcare providers afford to patient procedures can significantly help protect specimen integrity and improve downstream diagnostic accuracy.
Documentation Gaps: The Manual Transcription Problem
Even when a specimen is handled well, the data describing it often is not. Gross examination findings are still predominantly captured through long-form narrative dictation rather than structured formats. Dictated reports introduce inconsistent terminology across pathologists and institutions, and prognostically significant data elements, such as precise margin distances or lesion counts, are easy to omit from free text even when they were observed at the bench. This unstructured approach limits how that data can be reused for quality assurance, research, or integration with digital systems downstream. Structured or synoptic reporting frameworks at the point of gross examination address this directly, capturing discrete, consistently formatted data elements rather than relying on narrative recall to preserve what matters.
Traceability As A Data Integrity Issue
Specimen tracking gaps are a further, related contributor to data loss. When a specimen’s chain of custody is not documented consistently from collection through accessioning, the record of who handled it, when, and under what conditions becomes incomplete. While tracking gaps leave physical tissue intact, they strip away critical operational context needed to investigate downstream discrepancies. Traceability compounds the data loss driven by fixation and documentation failures.
What This Costs Downstream
When pre-analytical handling compromises specimen quality, the operational and financial tolls multiply across the clinical continuum. Upstream data loss manifests as misdiagnosis, repeat procedures, biomarker inaccuracy, staging errors, and delayed treatment—outcomes that negatively impact patient care and consume avoidable clinical resources.
Clinical And Diagnostic Consequences
Pre-analytical data loss has direct clinical consequences. Distorted morphology and degraded biomarkers increase the risk of misdiagnosis. Inadequate tissue sampling or documentation gaps can necessitate repeat procedures, delaying treatment for the patient. Staging errors, particularly around margin distance and lymph node yield, alter treatment planning in ways that are difficult to identify after the fact, since the original specimen condition cannot be reconstructed.
Constraints On Downstream Diagnostic Tools
Any diagnostic tool applied after the pre-analytical phase, including AI-assisted image analysis, is constrained by the data it receives. A model trained on or applied to degraded, inconsistently documented specimens cannot produce more reliable output than the input allows. Whatever gains in speed or consistency these tools offer downstream, they inherit the limitations set upstream.
Workforce Pressure Is Compounding the Gap
These pre-analytical vulnerabilities are intensifying alongside structural workforce pressure. The American Society for Clinical Pathology’s 2024 Vacancy Survey found that while laboratory vacancy rates have eased from their 2022 peak, they remain well above pre-pandemic levels, with retirements outpacing the pipeline of newly trained professionals. .[2] Fewer staff are managing rising specimen volumes and increasingly complex case types, conditions that make manual, error-prone pre-analytical steps harder to execute consistently.
As experienced personnel retire and vacancies persist, institutional knowledge that once compensated informally for the absence of structured processes becomes harder to rely on. This capacity constraint is a reason automation and standardization at the pre-analytical phase are becoming less optional and more necessary to sustaining data quality at scale.
Build Upstream Data Integrity Into the Workflow
Everything built on specimen data, from pathologist interpretation to biomarker analysis to any AI-assisted tool applied downstream, depends on getting this phase right first. Structured documentation, specimen imaging, and standardized protocols treat the pre-analytical phase as essential diagnostic infrastructure. Mopec’s grossing station technology is built around this principle, standardizing specimen documentation and imaging at the exact point where diagnostic data is either preserved or lost. Closing the pre-analytical data gap requires capturing complete, standardized specimen information at the bench before downstream analysis begins.
Data integrity begins before the slide exists. See how the Maestro Encore standardizes specimen documentation at the source.
References
- Katsma A, Jorns JM, Gardner P, Wolden M, Leuther K. Technical error prevalence in the complete pathology tissue testing process: a systematic review and meta-analysis. BMJ Open Qual. 2026 Feb 6;15(1):e003925. doi: 10.1136/bmjoq-2025-003925. PMID: 41651556; PMCID: PMC12887483.
- Edna Garcia, Jenny Diaz, Iman Kundu, Melissa Kelly, Ryan Soles, The American Society for Clinical Pathology 2024 Vacancy Survey of medical laboratories in the United States, American Journal of Clinical Pathology, Volume 164, Issue 5, November 2025, Pages 759–777, https://doi.org/10.1093/ajcp/aqaf101
